Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    ACP Recommends HIV Screening for All Patients, Regardless of Risk Factors - (DGNews)
    FDA Grants Full Approval of Maraviroc for Treatment-Experienced Patients With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 11/24/2008 - (DGNews)
    Early Antiretroviral Therapy and Mortality among HIV-Infected Infants - (N Engl J Med)
    Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - AIDS and HIV

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Soft Tissue Non-Hodgkin Lymphoma of Shoulder in a HIV Patient: A Report of a Case and Review of the Literature
      HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
      Primary Kaposi Sarcoma of the Subcutaneous Tissue
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      HIV-2 Diagnosis and Quantification in High-Risk Patients

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Atazanvir/Ritonavir Monotherapy Maintains Viral Suppression in Pilot Study: Presented at CROI

      By Ed Susman

      DENVER, CO -- February 8, 2006 -- Results of a small pilot study show that patients infected with HIV maintained viral suppression with atazanavir/ritonavir for at least 24 weeks after stopping their nucleoside analog therapy.

      "Simplified maintenance therapy with the boosted protease inhibitor atazanavir alone appears safe and effective. Larger, randomized trials are now warranted to define further the efficacy of this strategy," said researcher Susan Swindells, MBBS, the Terry K. Watanabe professor and medical director, HIV Clinic, University of Nebraska Medical Center, Omaha, Nebraska.

      Dr. Swindells discussed her study findings here on February 7th at the 13th Conference on Retroviruses and Opportunistic Infections (CROI).
      Dr. Swindells and colleagues began the study with 36 patients, all of whom had shown due diligence in maintaining adherence to highly active antiretroviral therapy (HAART) and had suppressed viral loads to undetectable levels using the 50-copy/mL assay for more than 1 year.

      Two patients were eliminated from the cohort before simplification could be started -- 1 withdrew consent and the other showed viral load blips above the detectable threshold and was not allowed in the study because of concerns that his virus was not fully suppressed.

      Of the remaining 34 patients, all but 3 continued to have undetectable viral loads. Dr. Swindells said 2 of the individuals had no signs of atazanavir in their bloodstream, an indication that they might have carried the simplification of the regimen further than was warranted. The third person had measurable atazanavir in his blood and was able to resuppress the virus to undetectable levels on boosted atazanavir alone.

      No resistant mutations were seen during the study period.

      "We have to emphasize that this is a pilot study; the numbers of patients are few, and these results are definitely preliminary in nature," commented John Mellors, MD, professor of medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

      "This study suggests that once you have induced suppression with a combination of drugs and have put a lid on the rapid replication of the virus, you may not need all the drugs," said Dr. Mellors.

      The trial was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.


      [Presentation title: A Prospective, Open-Label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression (ACTG 5201). Abstract 108LB]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send